SCHEDULE: BlackRock Discloses 5.1% Stake in Sana Biotechnology

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Sana Biotechnology Inc., holding 13,643,304 shares of common stock as of December 31, 2025.

Summary

• BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in Sana Biotechnology Inc.
• As of December 31, 2025, BlackRock beneficially owns 13,643,304 shares of Sana Biotechnology Inc. common stock.
• This represents 5.1% of the total outstanding common stock of Sana Biotechnology Inc.
• BlackRock holds sole voting power over 13,405,747 shares and sole dispositive power over 13,643,304 shares.
• The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Several BlackRock subsidiaries, including BlackRock Investment Management, LLC, are identified as beneficially owning shares.

Sentiment

Score: 7

Explanation: BlackRock's disclosure of a 5.1% passive stake in Sana Biotechnology Inc. suggests institutional confidence in the company. While a Schedule 13G is a routine disclosure and not an active endorsement, a substantial holding by a prominent asset manager like BlackRock is typically viewed favorably by the market.

Positives

• A major institutional investor like BlackRock holding a significant stake (5.1%) can be viewed as a vote of confidence in Sana Biotechnology Inc.
• The passive nature of the filing (Rule 13d-1(b)) suggests BlackRock is not seeking to influence management or control, indicating a long-term investment perspective.

Negatives

• The filing itself does not contain any negative information regarding Sana Biotechnology Inc.'s operations or financial performance.

Risks

• The filing does not discuss specific risks related to Sana Biotechnology Inc.'s business or operations, as it is a disclosure of ownership, not an operational report.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Sana Biotechnology Inc. or BlackRock regarding the issuer's future performance.

Industry Context

This filing reflects a large asset manager's investment decision within the biotechnology sector. Institutional ownership by firms like BlackRock is common across various industries, including biotech, where long-term growth potential is often a key investment driver.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a reputable firm like BlackRock may instill greater confidence among existing and potential shareholders, potentially stabilizing or positively influencing the stock price.
• Management: The passive nature of the investment (not seeking control) allows management to continue executing its strategy without immediate pressure from this specific large shareholder.

Key Dates

Recommendation

The filing indicates a significant passive stake by BlackRock, a major institutional investor. This suggests a degree of institutional confidence in Sana Biotechnology. However, the filing itself provides no new operational or financial data about Sana Biotechnology to warrant a 'buy' or 'sell' recommendation. It's a disclosure of ownership, not a performance report. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal of institutional interest while awaiting further operational updates from the company.

Keywords

Sana Biotechnology, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, Beneficial Ownership, Biotechnology, Investment